TrialsgrambetaRCTs are beautiful

STOP-CA

2023

Statins TO Prevent the Cardiotoxicity From Anthracyclines

In 300 patients with lymphoma scheduled for anthracycline-based chemotherapy, atorvastatin 40 mg daily for 12 months reduced the proportion of patients with an ejection-fraction decline of at least 10 % to below 55 % compared with placebo.

Result

Efficacy: Proportion with an absolute LVEF decline of ≥10 % to a final value below 55 % at 12 monthsodds ratio for placebo 2.9 (95% CI 1.4-6.4) · P = 0.002

Below 1 favours placebo, above 1 favours atorvastatin 40 mg daily for 12 months.

Event rates
Absolute difference
13 points
NNT
8

Absolute difference and NNT are derived from the event rates.

Also reported: Adjudicated heart failure 3 % vs 6 % (p=0.26; not significant).

Original publication
Subtopic
Statin cardioprotection
Design
Double-blind, placebo-controlled RCT
Relevance
Important: one of several pillars.
Source
Neilan TG, Quinaglia T, Onoue T, et al. JAMA. 2023;330(6):528-536.doi 10.1001/jama.2023.11887

Discussion & critique

The endpoint is an echocardiographic surrogate; the trial was not powered for heart failure, and clinical heart failure did not differ between arms. It is the largest positive statin trial in cardio-oncology and provides the randomised basis for statin cardioprotection in high-risk patients receiving anthracyclines.

Discussed in podcasts